Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma
| Autor: | Khaled Bzeizi, Mohammad Arabi, Fares Garad, Melfi Al-Otaibi, Ishtiaq Ahmed, Ali Benmousa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry Conventional transarterial chemoembolization Gastroenterology Retrospective cohort study hepatocellular carcinoma medicine.disease Surgery Dose–response relationship Median follow-up Internal medicine Hepatocellular carcinoma medicine Carcinoma lcsh:Diseases of the digestive system. Gastroenterology Original Article drug-eluting beads lcsh:RC799-869 Adverse effect business Survival rate Progressive disease |
| Zdroj: | Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association The Saudi Journal of Gastroenterology, Vol 21, Iss 3, Pp 175-180 (2015) |
| ISSN: | 1998-4049 1319-3767 |
| Popis: | Background/Aims: To compare the efficacy and safety profile of doxorubicin-loaded drug-eluting beads (DEB) to the conventional TACE (C-TACE) in the management of nonresectable hepatocellular carcinoma (HCC). Patients and Methods: All patients with nonresectable HCC who underwent either c-TACE or DEB-TACE during the period 2006–2014 and fulfilled the inclusion criteria were included in this retrospective study. Primary endpoints were tumor response rate at first imaging follow up, treatment-related liver toxicity, and treatment emergent adverse events (TEAE). Results: Thirty-five patients (51 procedures) in the DEB-TACE group and 19 patients (25 procedures) in the c-TACE group were included in the analysis. The median follow up time was 61 days (range 24– 538 days) in the DEB-TACE group and 86 days (range 3– 152 days) for the c-TACE group patients. Complete response (CR), objective response (OR), disease control (DC), and progressive disease (PD) rates were 11%, 24%, 17%, and 47%, respectively, in the DEB = TACE group compared with 4%, 32%, 28%, and 36%, respectively, in the c-TACE group. Mean ALT change from baseline was minimal in the DEB-TACE patients compared with c-TACE group (7.2 vs 79.4 units, P = 0.001). Hospital stay was significantly shorter in the DEB-TACE group (7.8 days vs 11.4 days; P = 0.038). The 2-year survival rate was 60% for the c-TACE patients and 58% for the DEB-TACE (P = 0.4). Conclusions: DEB-TACE compared with c-TACE is associated with lesser liver toxicity benefit, better tolerance, and shorter hospital stay. The two modalities however had similar survival and efficacy benefits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|